Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery

Journal of Cataract and Refractive Surgery

Volumn 39, Issue 2, 2013, Pages 168-173

  Lane, Stephen S ^a   Holland, Edward J ^b  

^a Associated Eye Care   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BESIFLOXACIN; BROMFENAC; LOTEPREDNOL ETABONATE; PREDNISOLONE ACETATE;

ADULT; AGED; ANTERIOR EYE CHAMBER; CATARACT EXTRACTION; CONFERENCE PAPER; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SURGICAL PATIENT; TOPICAL TREATMENT; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTERIOR CHAMBER; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZEPINES; BENZOPHENONES; BROMOBENZENES; CATARACT EXTRACTION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; POSTOPERATIVE COMPLICATIONS; PREDNISOLONE; TOPOISOMERASE II INHIBITORS; UVEITIS, ANTERIOR; VISUAL ACUITY;

EID: 84872817418     PISSN: 08863350     EISSN: 18734502     Source Type: Journal    
DOI: 10.1016/j.jcrs.2012.10.039     Document Type: Conference Paper

References (19)

1. C.E. Pavesio, and H.H. Decory Treatment of ocular inflammatory conditions with loteprednol etabonate Br J Ophthalmol 92 2008 455 459 (Pubitemid 351497967)
2. N. Bodor, T. Loftsson, and W.-M. Wu Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate Pharm Res 9 1992 1275 1278
3. P. Druzgala, W.-M. Wu, and N. Bodor Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes Curr Eye Res 10 1991 933 937
4. N. Bodor, and P. Buchwald Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems AAPS J 7 2005 E820 E833 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750951/pdf/ 12248-2008-Article-74820.pdf Accessed October 30, 2012
5. J.D. Bartlett, B. Horwitz, R. Laibovitz, and J.F. Howes Intraocular pressure response to loteprednol etabonate in known steroid responders J Ocul Pharmacol 9 1993 157 165 (Pubitemid 23187584)
6. G.D. Novack, J. Howes, R.S. Crockett, and M.B. Sherwood Change in intraocular pressure during long-term use of loteprednol etabonate J Glaucoma 7 1998 266 269 (Pubitemid 29149820)
7. S.J. Dell, D.G. Schulman, G.M. Lowry, and J. Howes A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis; Loteprednol Allergic Conjunctivitis Study Group Am J Ophthalmol 123 1997 791 797 (Pubitemid 27250926)
8. P. Asbell, and J. Howes A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis CLAO J 23 1997 31 36 (Pubitemid 27043763)
9. M.H. Friedlander, and J. Howes A double-masked, placebo controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis; the Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I Am J Ophthalmol 123 1997 455 464 (Pubitemid 27171850)
10. The Loteprednol Etabonate US Uveitis Study Group Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis Am J Ophthalmol 127 1999 537 544
11. S.C. Pflugfelder, S.L. Maskin, B. Anderson, J. Chodosh, E.J. Holland, C.S. De Paiva, S.P. Bartels, T. Micuda, H.M. Proskin, and R. Vogel A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for the treatment of keratoconjunctivitis sicca in patients with delayed tear clearance Am J Ophthalmol 138 2004 444 457 (Pubitemid 39208573)
12. R. Stewart, B. Horwitz, J. Howes, G.D. Novack, and K. Hart Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation; Loteprednol Etabonate Post-Operative Inflammation Study Group 1 J Cataract Refract Surg 24 1998 1480 1489 (Pubitemid 28509816)
13. The Loteprednol Etabonate Postoperative Inflammation Study Group 2 A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation Ophthalmology 105 1998 1780 1786
14. T.L. Comstock, M.R. Paterno, A. Singh, T. Erb, and E. Davis Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery Clin Ophthalmol 5 2011 177 186 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045067/pdf/opth-5- 177.pdf Accessed October 30, 2012
15. E.J. Holland, J.D. Bartlett, M.R. Paterno, D.W. Usner, and T.L. Comstock Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers Cornea 27 2008 50 55
16. E.M. White, J.I. Macy, K.M. Bateman, and T.L. Comstock Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis Curr Med Res Opin 24 2008 287 296 (Pubitemid 351181204)
17. M.S. Korenfeld, S.M. Silverstein, D.L. Cooke, R. Vogel, R.S. Crockett Difluprednate Ophthalmic Emulsion 0.05% (Durezol) Study Group Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain J Cataract Refract Surg 35 2009 26 34
18. W. Stringer, and R. Bryant Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1% Clin Ophthalmol 4 2010 1119 1124 Available at: http://www.dovepress.com/getfile.php?fileID=7784 Accessed October 30, 2012
19. U.S. National Institutes of Health. Clinical Trials. A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery, Study number NCT01384266. Available at: http://www.clinicaltrials.gov/ ct2/show/NCT01384266?term=nct01384266&rank=1. Accessed October 30, 2012